Get the Stockscreener App
12.37
2.87%
0.345
Angiodynamic Inc stock is traded at $12.37, with a volume of 623.99K.
It is up +2.87% in the last 24 hours and down -20.28% over the past month.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
See More
Previous Close:
$12.02
Open:
$11.93
24h Volume:
623.99K
Relative Volume:
0.61
Market Cap:
$520.00M
Revenue:
$320.17M
Net Income/Loss:
$-36.74M
P/E Ratio:
-13.96
EPS:
-0.8856
Net Cash Flow:
$-2.86M
1W Performance:
+10.01%
1M Performance:
-20.28%
6M Performance:
+10.40%
1Y Performance:
+3.04%
1-Day Range:
$11.76
$12.47
1-Week Range:
$11.09
$12.47
52-Week Range:
$9.39
$16.29
Angiodynamic Inc Stock (ANGO) Company Profile
Name
Angiodynamic Inc
Sector
Industry
Phone
(518) 798-1215
Address
14 PLAZA DRIVE, LATHAM
Compare ANGO vs ISRG, BDX, RMD, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANGO
Angiodynamic Inc
|
12.37 | 520.00M | 320.17M | -36.74M | -2.86M | -0.8856 |
ISRG
Intuitive Surgical Inc
|
452.29 | 159.78B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
198.91 | 54.18B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
252.86 | 35.56B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
70.17 | 33.92B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.09 | 29.91B | 29.14B | 1.07B | 1.05B | 1.1956 |
Angiodynamic Inc Stock (ANGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Initiated | Lake Street | Buy |
| Apr-05-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-25-23 | Initiated | H.C. Wainwright | Buy |
| Apr-17-23 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-15-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-20-21 | Initiated | Oppenheimer | Perform |
| Nov-25-20 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Apr-08-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-01-19 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Apr-03-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-18 | Downgrade | Craig Hallum | Buy → Hold |
| Apr-07-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Mar-30-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
| Feb-08-17 | Initiated | Barclays | Equal Weight |
| Nov-04-16 | Initiated | Cantor Fitzgerald | Buy |
| Apr-08-16 | Resumed | Piper Jaffray | Neutral |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Nov-10-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-24-15 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jun-19-14 | Upgrade | Canaccord Genuity | Hold → Buy |
| Oct-09-12 | Reiterated | Canaccord Genuity | Hold |
| Jun-25-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-15-11 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-15-11 | Upgrade | Stifel Nicolaus | Hold → Buy |
| Jun-14-11 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-08-10 | Reiterated | Wedbush | Neutral |
View All
Angiodynamic Inc Stock (ANGO) Latest News
AngioDynamics (ANGO) Advances Pancreatic Cancer Treatment with N - GuruFocus
AngioDynamics study shows survival benefit for pancreatic cancer - Investing.com
A pancreatic cancer study linked an electrical-pulse approach to 28 months’ median survival versus 15. - Stock Titan
AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist (NASDAQ:ANGO) - Seeking Alpha
Humana applies Medicare coverage rules to a non-heat treatment for some prostate and liver cancer patients. - Stock Titan
A Look at AngioDynamics Inc (ANGO) After 4.4% Decline -- GF Value $10.48 vs Price $10.90 - GuruFocus
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - Zacks Investment Research
ANGIODYNAMICS INC ($ANGO) President, CEO 2026 Pay Revealed - Quiver Quantitative
AngioDynamics CLO Received Pay Boost To $1.5M Last Year - Law360
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates - Zacks Investment Research
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability - Yahoo Finance
AngioDynamics Q1 Earnings Call Highlights - TradingView
AngioDynamics, Inc. Q1 2027 Earnings Call Summary - Yahoo Finance
With its CEO set to retire, AngioDynamics (ANGO) names a Getinge executive as successor. - Stock Titan
AngioDynamics, Inc. 2027 Q1ResultsEarnings Call Presentation (NASDAQ:ANGO) 2026-10-08 - Seeking Alpha
AngioDynamics, Inc. reports results for the quarter ended August 31Earnings Summary - TradingView
AngioDynamics Shares Fall 4.3% Despite Q1 Earnings Beat and Strong Med Tech Growth - Yahoo Finance
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer - Yahoo Finance
AngioDynamics: Fiscal Q1 Earnings Snapshot - Yahoo Finance
AngioDynamics stock slips 4% despite beating estimates on Med Tech growth - Yahoo Finance
AngioDynamics Inc (ANGO) (Q1 2027) Earnings Call Highlights: MedTech Momentum Drives 6. ... - Yahoo Finance
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Why AngioDynamics Crashed Today - Yahoo Finance
ANGIODYNAMICS Q1 2027 Earnings Preview: Recent $ANGO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
AngioDynamics, Inc. (ANGO) Stock Price, News, Quote & History - Yahoo! Finance Canada
A Bronx hospital won a research award to test if scans can predict clot-removal success. - Stock Titan
A successor's appointment could set the CEO's retirement date at AngioDynamics (ANGO). There's another trigger. - Stock Titan
AngioDynamics Fiscal 2026 Net Loss Widens to $36.7 Million - Minichart
Sales reached $320.2 million at AngioDynamics (ANGO). Five executives received cash bonuses. - Stock Titan
AngioDynamics, Inc. (ANGO) stock price, news, quote and history - Yahoo Finance UK
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 - Yahoo Finance Australia
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 - Yahoo Finance
AngioDynamics, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView
How Angiodynamics Inc. (ANGO) Affects Rotational Strategy Timing - Stock Traders Daily
AngioDynamics Inc. (ANGO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
387,188 Shares in AngioDynamics, Inc. $ANGO Bought by Western Standard LLC - MarketBeat
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth ConferenceSlideshow - Seeking Alpha
AngioDynamics, Inc. (ANGO) Stock Analysis: Uncovering a 32% Potential Upside with Robust Buy Ratings - DirectorsTalk Interviews
AngioDynamics SmartPort Infection Lawsuit Alleges Defective Port Caused Sepsis - aboutlawsuits.com
AngioDynamics, Inc. $ANGO Shares Purchased by Lazard Asset Management LLC - MarketBeat
Senior Vice President of Regulatory Affairs Warren Nighan Sold A Bunch Of Shares In AngioDynamics - simplywall.st
Segall Bryant & Hamill LLC Trims Stock Position in AngioDynamics, Inc. $ANGO - MarketBeat
AngioDynamics, Inc. (NASDAQ:ANGO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
AngioDynamics (ANGO) SVP Warren Nighan Jr. sells 23,370 shares at $14.72 - Stock Titan
AngioDynamics (NASDAQ: ANGO) insider plans $344K sale of equity awards - Stock Titan
AngioDynamics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Live webcast set for AngioDynamics' Aug. 11 presentation - Stock Titan
AngioDynamics Inc (ANGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AngioDynamics, Inc. Revenue Breakdown – NASDAQ:ANGO - TradingView
Angiodynamic Inc Stock (ANGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Angiodynamic Inc Stock (ANGO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WARREN NIGHAN | Officer |
Jul 30 '26 |
Proposed Sale |
14.72 |
23,370 |
344,004 |
0 |
| Piccinini Laura | SVP International |
Jul 22 '26 |
Option Exercise |
0.00 |
8,047 |
0 |
86,435 |
| Nighan Warren JR | SVP Quality and Regulatory |
Jul 22 '26 |
Option Exercise |
0.00 |
5,694 |
0 |
89,786 |
| Trowbridge Stephen A | EVP and CFO |
Jul 22 '26 |
Option Exercise |
0.00 |
16,296 |
0 |
314,115 |
| Clemmer James C | President and CEO |
Jul 22 '26 |
Option Exercise |
0.00 |
52,358 |
0 |
889,176 |
| Campbell Chad Thomas | SVP/GM, Vascular Access |
Jul 22 '26 |
Option Exercise |
0.00 |
6,466 |
0 |
111,006 |
| Weiss Lawrence T | SVP, Chief Legal Officer |
Oct 21 '25 |
Buy |
11.81 |
10,000 |
118,100 |
93,597 |
| Trowbridge Stephen A | EVP and CFO |
Oct 13 '25 |
Buy |
11.16 |
890 |
9,932 |
256,629 |
| Clemmer James C | President and CEO |
Oct 09 '25 |
Buy |
11.15 |
10,000 |
111,500 |
882,529 |
2.19%
8.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):